ArticleThe Journal of clinical investigation1993
Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. Role of Ca2+ mobilization and protein kinase C activation.
Article in The Journal of clinical investigation, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 156 citations in OpenAlex.
- Renin-angiotensin imbalance promotes excessive fibrin deposition through M2 macrophage-derived tissue factor expression in eosinophilic chronic rhinosinusitis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Impact of tissue factor expression and administration routes on thrombosis development induced by mesenchymal stem/stromal cell infusions: re-evaluating the dogma.Stem cell research & therapy · 2024Article
- Endothelial-derived microvesicles promote pro-migratory cross-talk with smooth muscle cells by a mechanism requiring tissue factor and PAR2 activation.Frontiers in cardiovascular medicine · 2024Article
- Rivaroxaban attenuates cardiac hypertrophy by inhibiting protease-activated receptor-2 signaling in renin-overexpressing hypertensive mice.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Article
- The Impact of the Renin-Angiotensin-Aldosterone System on Inflammation, Coagulation, and Atherothrombotic Complications, and to Aggravated COVID-19.Frontiers in pharmacology · 2021Review
- Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.Frontiers in immunology · 2021Review
- Beyond thrombosis: the impact of tissue factor signaling in cancer.Journal of hematology & oncology · 2020Review
- Monocytes as immune targets in arterial hypertension.British journal of pharmacology · 2019Review
- A unique protein kinase C-dependent pathway for tissue factor downregulation in pericytes.Journal of thrombosis and haemostasis : JTH · 2019Article
- KLF11 (Krüppel-Like Factor 11) Inhibits Arterial Thrombosis via Suppression of Tissue Factor in the Vascular Wall.Arteriosclerosis, thrombosis, and vascular biology · 2019Article
- Impact of angiotensin-converting enzyme inhibition on platelet tissue factor expression in stroke-prone rats.Journal of hypertension · 2018Article
- Angiotensin II promotes the anticoagulant effects of rivaroxaban via angiotensin type 2 receptor signaling in mice.Scientific reports · 2017Article
- Tissue factor, protease activated receptors and pathologic heart remodelling.Thrombosis and haemostasis · 2014Review
- Bivalirudin in combination with heparin to control mesenchymal cell procoagulant activity.PloS one · 2012Article
- Oxidative risk for atherothrombotic cardiovascular disease.Free radical biology & medicine · 2009Review
- Role of the renin angiotensin system in TNF-alpha and Shiga-toxin-induced tissue factor expression.Pediatric nephrology (Berlin, Germany) · 2008Article
- Tissue factor and nitric oxide: a controversial relationship!Journal of thrombosis and thrombolysis · 2007Review
- Tissue factor; from Morawitz to microparticles.Transactions of the American Clinical and Climatological Association · 2007Review
- HIV envelope gp120 activates human arterial smooth muscle cells.Proceedings of the National Academy of Sciences of the United States of America · 2001Article
- Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy.The American journal of pathology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Tissue factor (TF) is a low molecular weight glycoprotein that initiates the clotting cascade and is considered to be a major regulator of coagulation, hemostasis, and thrombosis. TF is not expressed in the intima or media of normal adult blood vessels. Accordingly, it has been hypothesized that the initiation of intravascular coagulation may require the "induced" expression of TF in the vessel wall. We report that TF mRNA and protein are rapidly and markedly induced in early and late passaged vascular smooth muscle cells (VSMC) by growth factors (serum, platelet-derived growth factor, epidermal growth factor), vasoactive agonists (angiotensin II), and a clotting factor (alpha-thrombin). The induction of TF mRNA by these agents is dependent upon mobilization of intracellular Ca2+ and is blocked by Ca2+ chelation. In contrast to other growth factor-responsive genes, such as KC and c-fos, downregulation of protein kinase C activity by prolonged treatment with phorbol esters fails to block agonist-mediated TF induction. This raises the possibility that protein kinase C activation may not be necessary for TF mRNA induction in VSMC. VSMC may play a role in the generation or propagation of thrombus through the induction of TF, particularly in settings, such as those associated with acute vessel injury, where the endothelium is denuded and the VSMC are exposed to circulating blood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.